INHBB: A Protein Targeted for Cancer and Neurodegenerative Diseases

Target Name: INHBB

NCBI ID: G3625

INHBB

INHBB: A Protein Targeted for Cancer and Neurodegenerative Diseases

INHBB (activin beta-B chain), also known as INHB尾2, is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the development and maintenance of tissues, including the nervous system, muscle system, and heart. INHBB is a key regulator of the growth and differentiation of these tissues and is involved in a wide range of physiological processes.

Disease and Treatment

INHBB is involved in a number of diseases and treatments. One of the most significant is cancer, where INHBB has been shown to promote the growth and survival of cancer cells. This is because INHBB plays a role in the cell signaling pathway known as the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

Another area where INHBB has been shown to be involved in disease treatment is neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a wide range of symptoms, including cognitive decline, tremors, and difficulty with daily activities.

Research has also shown that INHBB is involved in the development of cardiovascular disease, including heart failure and hypertension. By regulating the growth and differentiation of heart cells, INHBB may be involved in the development of these conditions.

Drugs and Treatments

Given the involvement of INHBB in a wide range of diseases and physiological processes, researchers have been actively seeking new treatments for INHBB-related conditions. One potential approach to treating INHBB-related diseases is to target INHBB itself with drugs.

One such drug is a small molecule inhibitor of the TGF-β pathway, known as TG-4012. This drug has been shown to reduce the growth and survival of cancer cells that express INHBB. In addition, TG-4012 has been shown to protect against the toxic effects of radiation in animal models of cancer.

Another potential approach to treating INHBB-related diseases is to target INHBB with antibodies that can specifically bind to INHBB and prevent it from functioning. One such approach is a monoclonal antibody (MAb) that targets INHBB.

The use of antibodies to treat INHBB-related diseases has been shown to be effective in animal models. For example, researchers have shown that an MAb against INHBB can effectively reduce the growth and survival of cancer cells that express INHBB.

Conclusion

INHBB is a protein that plays a crucial role in the development and maintenance of various tissues throughout the body. Its involvement in a wide range of physiological processes makes it an attractive target for new treatments for a variety of diseases. The use of small molecules and antibodies to target INHBB has shown promise in animal models, and further research is needed to determine its effectiveness in humans.

Protein Name: Inhibin Subunit Beta B

Functions: Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins

The "INHBB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INHBB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets